Avacta, Daewoong partner on COVID-19 therapy

By The Science Advisory Board staff writers

July 29, 2020 -- Avacta has expanded its collaboration with Daewoong Pharmaceutical to develop stem cell treatments using Avacta's neutralizing Affimer therapy for COVID-19 patients.

AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong, will develop a novel class of mesenchymal stem cell treatments that are engineered to also produce Affimer therapies in patients at a selected site of action.

Now, the collaboration will also include the development of therapies that repair lung damage caused by COVID-19 while also producing neutralizing Affimer molecules that prevent disease progression.

Avacta's Affimer reagent may neutralize SARS-CoV-2
Avacta Group, the developer of Affimer biotherapeutics and reagents, announced that several Affimer reagents block the interaction between SARS-CoV-2's...

Copyright © 2020 scienceboard.net

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter